Infectious Tenosynovitis Organism-Specific Therapy 

No Results

No Results

processing….

Organism-specific therapeutic regimens for infectious tenosynovitis are provided below, including those for the following pathogens:

Staphylococcus aureus (methicillin susceptible)  ^{[1, 2, 3, 4]}

Staphylococcus aureus (methicillin resistant)  ^{[5, 1, 6, 7, 8]}

Streptococcus species  ^[9]

Pseudomonas aeruginosa ^{[10, 11]}

Neisseria gonorrhoeae ^[12]

All of the preceding regimens should be continued for 24-48 hours after improvement begins, at which time therapy can be switched to cefixime 400 mg PO BID to complete at least 1 week of antimicrobial therapy

Pasteurella multocida ^[13]

Mycobacterium marinum ^{[14, 15]}

For treatment of Mycobacterium tuberculosis infection, please refer to Tuberculosis Organism-Specific Therapy.

Sporothrix schenckii ^[16]

Coccidioides  species  ^{[17, 18, 19]}

Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998 Aug 20. 339(8):520-32. [Medline].

Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011 Oct 19. 11:279. [Medline]. [Full Text].

Del Río A, García-de-la-Mària C, Entenza JM, Gasch O, Armero Y, Soy D, et al. Fosfomycin plus Beta-lactams: Synergistic Bactericidal Combinations in Methicillin-resistant (MRSA) and Glycopeptide-Intermediate Resistant (GISA) Staphylococcus aureus Experimental Endocarditis. Antimicrob Agents Chemother. 2015 Nov 2. [Medline].

Berti AD, Theisen E, Sauer JD, Nonejuie P, Olson J, Pogliano J, et al. Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for β-lactam-daptomycin synergy. Antimicrob Agents Chemother. 2015 Nov 2. [Medline].

Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1. 52(3):e18-55. [Medline].

Frei CR, Miller ML, Lewis JS 2nd, et al. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med. 2010 Nov-Dec. 23(6):714-9. [Medline].

Inomata S, Yano H, Tokuda K, Kanamori H, Endo S, Ishizawa C, et al. Microbiological and molecular epidemiological analyses of community-associated methicillin-resistant Staphylococcus aureus at a tertiary care hospital in Japan. J Infect Chemother. 2015 Oct. 21 (10):729-36. [Medline].

Metsemakers WJ, Emanuel N, Cohen O, Reichart M, Potapova I, Schmid T, et al. A doxycycline-loaded polymer-lipid encapsulation matrix coating for the prevention of implant-related osteomyelitis due to doxycycline-resistant methicillin-resistant Staphylococcus aureus. J Control Release. 2015 Jul 10. 209:47-56. [Medline].

Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: New concepts in antibiotic treatment. Int J Antimicrob Agents. 1994. 4(4):297-301. [Medline].

Pappas G, Saplaoura K, Falagas ME. Current treatment of pseudomonal infections in the elderly. Drugs Aging. 2009. 26(5):363-79. [Medline].

Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 2005 Jul. 11 Suppl 4:17-32. [Medline].

Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5912a1.htm. Accessed: August 20, 2013.

Goldstein EJ. Bite wounds and infection. Clin Infect Dis. 1992 Mar. 14(3):633-8. [Medline].

Aubry A, Chosidow O, Caumes E, Robert J, Cambau E. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med. 2002 Aug 12-26. 162(15):1746-52. [Medline].

Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15. 175(4):367-416. [Medline].

Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007 Nov 15. 45(10):1255-65. [Medline].

Campbell M, Kusne S, Renfree KJ, Vikram HR, Smilack JD, Seville MT, et al. Coccidioidal Tenosynovitis of the Hand and Wrist: Report of 9 Cases and Review of the Literature. Clin Infect Dis. 2015 Nov 15. 61 (10):1514-20. [Medline].

Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000 Nov 7. 133 (9):676-86. [Medline].

Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, et al. Coccidioidomycosis. Clin Infect Dis. 2005 Nov 1. 41 (9):1217-23. [Medline]. [Full Text].

Jefferson R Roberts, MD Chief of Rheumatology Service, Tripler Army Medical Center; Assistant Clinical Professor of Medicine, Uniformed Services University of the Health Sciences

Jefferson R Roberts, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Society for Simulation in Healthcare

Disclosure: Nothing to disclose.

Sharon W Chi, DO Resident Physician, Department of Internal Medicine, Tripler Army Medical Center

Sharon W Chi, DO is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Thomas E Herchline, MD Professor of Medicine, Wright State University, Boonshoft School of Medicine; Medical Consultant, Public Health, Dayton and Montgomery County (Ohio) Tuberculosis Clinic

Thomas E Herchline, MD is a member of the following medical societies: Alpha Omega Alpha, Infectious Diseases Society of America, Infectious Diseases Society of Ohio

Disclosure: Nothing to disclose.

Jeremy W Docekal, MD Medical Intern, Department of Internal Medicine, Tripler Army Medical Center

Jeremy W Docekal, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Kelley Struble, DO Fellow, Department of Infectious Diseases, University of Oklahoma College of Medicine

Kelley Struble, DO is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Infectious Tenosynovitis Organism-Specific Therapy 

Research & References of Infectious Tenosynovitis Organism-Specific Therapy |A&C Accounting And Tax Services
Source

Share on Facebook

Tweet

Follow us